Marriott International Inc vs Neurocrine Biosciences Inc — how do they compare? Marriott International Inc trades at $351.69 (market cap $91.14B), while Neurocrine Biosciences Inc trades at $155.49 (market cap $16.46B). The key difference: Marriott International Inc is far larger — about 5.5× Neurocrine Biosciences Inc's market cap, and Marriott International Inc pays a 0.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MAR | NBIX | |
|---|---|---|
Market Cap | $91.14B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $185.50 |
52-Week Low | $259.04 | $123.10 |
Enterprise Value | $108.45B | $16.48B |
Dividend Yield | 0.84% | — |
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $348.44, down 1.55% on the day, with a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $3.19, beating estimates, but revenue growth faces headwinds. Key risks include high debt levels and valuation concerns, while analyst consensus remains positive with a $387.31 price target.
Outlook: MAR's fee-based model and loyalty program drive growth, but elevated P/E of 36.18 and rising debt-to-asset ratio warrant caution. Upside hinges on sustained RevPAR gains and effective cost management amid global economic uncertainty.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →